Mantle Cell Lymphoma: Clinical Characteristics, Prevalence and Treatment Options

Charles L. Schmidt (Editor)

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin’s Lymphoma (NHL) with varying clinical presentations, ranging from indolent disease to highly aggressive symptoms. MCL represents approximately 3-10% of non-Hodgkin lymphomas, and has increased in incidence over the past several decades. The majority of patients respond to initial therapy, but remission duration is typically short. This book discusses the clinical characteristics of mantle cell lymphoma, as well as it’s prevalence and examines several treatment options available. (Imprint: Nova Biomedical)


Chapter 1. Diagnosis, Prognosis and Genetic Features of Mantle Cell Lymphoma
Haipeng Shao, Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Chapter 2. Mantle Cell Lymphoma: Current Treatment Strategies in the Era of Targeted Agents
Muhammad Omer Jamil, Maira Rizwan, Amitkumar Mehta, Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Chapter 3. Targeted Drugs in the Treatment of Mantle Cell Lymphoma
Piotr Smolewski, Magdalena Witkowska, Tadeusz Robak, Department of Experimental Hematology, and Department of Hematology, Medical University of Lodz, Poland

Chapter 4. Emerging Role of Novel Agents in the Treatment of Mantle Cell Lymphoma
Bridgette A. Kanz, Mahsa S. Talbott, Nishitha M. Reddy, Department of Pharmacology, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA

Chapter 5. Current Place of Proteasome Inhibitors in the Treatment of Mantle Cell Lymphoma
Panagiotis J. Vlachostergios, Rajeev L. Balmiki, Department of Internal Medicine, Lutheran Medical Center, Brooklyn, NY, USA


You have not viewed any product yet.